• SENSEX  
    ( -0.37%)
  • USDINR  
    ( 0.33%)
  • GOLD  
    ( 1.55%)
  • Hot Pursuit - Detailed News
Laurus Labs turns volatile after Q3 results
31-Jan-20   11:59 Hrs IST

Profit before tax (PBT) stood at Rs 81.71 crore in Q3 December 2019, up by 258.8% from Rs 22.77 crore reported in Q3 December 2018.

Net sales of the company surged 37.8% to Rs 729.59 crore in Q3 December 2019 from Rs 529.46 crore in Q3 December 2018.

EBITDA jumped 68% to Rs 150 crore in Q3 December 2019 over Q3 December 2018. EBITDA margins in the December quarter stood at 21%.

Commenting on the results announcement, Dr. Satyanarayana Chava - CEO said: Our Formulations business led by Low Middle Income Countries (LMIC) tenders has delivered significant growth in a very short time, resulting in an approximately 30% contribution to revenues on a 9M FY20 basis. With an enhanced focus on growth opportunities arising from LMIC markets, the contribution from the FDF (finished dosage form) business is expected to improve further. The growth in the developed markets will be driven by our product-specific approach. Other API (active pharmaceutical ingredient) division has maintained its strong growth trajectory from previous quarters. The introduction of new high-value products continues to drive growth. However, our ARV (antiretroviral) API revenues were lower mainly because of lower offtake in the South Africa market due to delays in Supplementary tenders. With our margins improving consistently in FY20 I am very pleased to see that we are on a high growth track.

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said, “Gross Margins continue to improve with Formulations business along with a change in product mix and softening of some raw material prices. Also, with the improved operating leverage, our EBITDA margins have shown improvement at 21% for Q3FY20 & 19% for 9M FY20. Our Asset utilization rates have improved with Unit 2 running at near full capacity. With attractive business opportunities and healthy order book for FY21, we continue to invest in our FDF Infrastructure. At the same time, we remain confident of achieving positive Free Cashflows (FCF) status from FY21 onwards.”

Laurus Labs operates as a pharmaceutical company. The company researches, develops, and manufactures active pharmaceutical ingredients for therapeutic areas of anti-retrovirals and hepatitis C. The drug maker serves customers worldwide.

Shares of Laurus Labs fell 2.13% to Rs 427. The stock jumped as much as 5.43% to hit the day's high at Rs 460 in morning trade, which is also a 52-week high for the scrip.

Powered by Capital Market - Live News

Useful Links

Back to Top
Attention Investors
Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day.............issued in the interest of investors. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account                                    "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Investors should be cautious of unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.BSE   http://www.bseindia.com/investors/tip-off-registration.aspx?expandable  NSE   https://www.nseindia.com/int_invest/dynacontent/any_portal.htm
All payments to Stock Broker shall be received from the market intermediaries/participants strictly by account payee crossed cheques / demand drafts or by way of direct credit into the bank account through electronic fund transfer, or any other mode permitted by the Reserve Bank of India. Stock Brokers shall not accept cash from their clients either directly or by way of cash deposit to the Bank Account of Stock Broker.
Group Companies Members of : BSE, NSE, MCX, MCX.SX, CDSL, NCDEX, Broking Services, Depository Services, Portfolio Management Services, Member Area IPO Distribution, Insurance Broking
BSE Clearing No.: 911 | SEBI Regn. No.: INZ000177531 (Cash/F&O) | NSE Clearing No.: 11858 | SEBI Regn. No. INZ000177531 (Cash/F&O/CDs) | MCX-SX Clearing No.: 11400 | SEBI Regn. No.: INZ000177531 (CDs) | CDSL DP ID: 30300 | SEBI Regn. No.: IN-DPCDSL-210-2003 | MCX SEBI Reg No.: INZ000032336 | MCX: 10665 | NCDEX: 00254 | NBFC RBI Regn. No.: 13.01851
© Copyright 2018 Ajmera Associates Ltd ( ISO 9001:2015 Certified )
Designed, Developed and Powered By CMOTS Infotech ( ISO 9001:2015 Certified )
Open An Account Today !